In collaboration with the University of Michigan, we published our first IRB-approved study in 2016. We are awaiting publication for our second follow-up study now and are in the process of two more IRB-approved studies!
Our First Research Study:
We conducted a survey of 244 medical cannabis patients in Michigan with chronic pain for 3 months. Our goal was to collect data to examine if using medical cannabis for chronic pain affected one’s opioid consumption as well. We saw testimonial evidence of this everyday in our consultation rooms. Click the link below to read our study that was published in the Journal of Pain!
Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain (2016)
Three Major Conclusions:
- Cannabis use was associated with 64% lower opioid use in patients with chronic pain.
- Cannabis use was associated with better quality of life in patients with chronic pain.
- Cannabis use was associated with fewer medication side effects and medications used.
Impact Since Published:
After publication in 2016, our study has been cited in several important reports including
- National Academies of Sciences, Engineering & Medicine Report: The Health Effects of Cannabis and Cannabinoids
- Physicians Guide to Cannabis-Assisted Opioid Reduction: Distributed to Congress
Our Nationwide Follow-up Study:
We partnered again with the University of Michigan and received IRB-approval for our second research study in 2018, titled: “Longitudinal examination of medical cannabis for central nervous system pain reduction.” By widening our reach from only Michigan patients to cardholders across many medical states, we are able to further implicate our findings on larger, more encompassing level.
Our goal is to further examine how cannabis use is related to pain management, quality of life, and the use of other medications. We can use the information collected to not only help our patients directly but help inform physicians, researchers, policy-makers about the potential benefits and risk of cannabis as a therapeutic agent.